To evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy(ADT) and standard salvage radiation therapy(SRT) or SRT combination with ADT in prostate cancer patients with biochemical recurrence of prostate-specific antigen(PSA) persistence after radical prostatectomy(RP).
1. ≥40 years old, male;
2. Postoperative pathology showed prostate adenocarcinoma;
3. Postoperative pathological stage pN0 or pNx;
4. PSA decline < 0.1ng/ml within 8 weeks after radical prostate cancer surgery for at least 6 months
1. Previously received endocrine therapy for prostate cancer (including but not limited to goserrelin, levoprorelin, digarek, bicalutamide, abiraterone acetate, darotamine, apatamide, enzalutamide, etc.) or pelvic radiotherapy;
2. Postoperative biochemical recurrence, but PSA more than 2 ng/ml;
3. Postoperative pathology contains non-adenocarcinoma components, such as neuroendocrine differentiation or small cell features;
4. Is currently participating in or has participated in an investigational drug study;